Author Correction: Utilization of peginterferon- β-1a in the real-world practice for relapsing-remitting multiple sclerosis

Conclusions section of the abstract, "SC PEG-IFN-β-1a and IFN- β-1a" is corrected to "PEG-IFN-β-1a and SC IFN-β-1a". • In the Population section, the study period "January 1st 2015 to December 31st 2019" was not reported; therefore, this specification has been added to the text. • The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is "Study flow diagram". • Under Tables I, II, and III, "interferon beta 1a IFN-β-1a" is corrected to "interferon beta 1a (IFN-β-1a)". • In Table III, "CS Glatiramer acetate" is corrected to "SC Glatiramer acetate". • In the Conclusions section, "SC IFN-β-1a SC" is corrected to "SC IFN-β-1a". • The funding section has been amended as follows: "This study was sponsored by Biogen Italia (Milan, Italy)." There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/34930.PMID:38436157 | DOI:10.26355/eurrev_202402_35445

Source: Pharmacological Reviews - March 4, 2024 Category: Drugs & Pharmacology Authors: M Moccia L Santoni I Vaccari G Affinito D Caliendo F Rubba R Lanzillo M Triassi V Brescia Morra R Palladino Source Type: research